



**PROFICIENCY TESTING SERVICE  
AMERICAN ASSOCIATION OF BIOANALYSTS**

205 West Levee St. ♦ Brownsville, TX 78520-5596  
800-234-5315 ♦ 956-546-5315 ♦ Fax 956-542-4041

**ANTIMICROBIAL SUSCEPTIBILITIES**

**PARTICIPANT STATISTICS**

**THIRD QUADRIMESTER 2011**

**ANTIMICROBIAL SUSCEPTIBILITIES vs. *Enterobacter aerogenes***

Antimicrobial Agent	*CLSI Group	Resistant					Intermediate					Susceptible				
		Code	A-D	Bkpt	MIC	Total	Code	A-D	Bkpt	MIC	Total	Code	A-D	Bkpt	MIC	Total
Amikacin	B	102			1	1	202					302	25	25	70	131
Amoxicillin/clavulanate	B	104	70	27	55	161	204			1	1	304	4	2		6
Ampicillin	A	105	98	28	50	185	205	6	7	11	25	305	9	4	3	20
Ampicillin/sulbactam	B	107		7	8	15	207		3	12	15	307	3	16	21	44
Aztreonam	C	110		1		1	210			1	1	310	6	23	25	59
Carbenicillin	O	111				1	211					311	31		2	35
Cefazolin	A	116	16	39	93	158	216	2			2	316	5	3		8
Cefixime	O	117					217					317	9		2	11
Cefotaxime	B	125		1		1	225			1	1	325	11	25	33	75
Cefotetan	B	126		3	1	4	226			1	1	326	5	6	5	17
Cefoxitin	B	128	20	29	42	94	228					328	2	2	1	5
Ceftazidime	C	129		1		1	229			1	1	329	18	25	54	104
Ceftriaxone	B	132		1		1	232			1	1	332	50	37	73	170
Cefuroxime/Cef Axetil	B	134		1	6	7	234	1			1	334	21	9	12	46
Cephalothin	U	137	92	20	22	142	237					337	1			2
Ciprofloxacin	B	141			2	2	241		1		1	341	131	38	98	283
Gatifloxacin	O	145			1	1	245					345		1	10	15
Gentamicin	A	153		1		1	253					353	108	41	101	265
Imipenem	B	155					255					355	18	32	72	130
Levofloxacin	B	154		1	1	2	254			1	1	354	62	34	86	195
Meropenem	B	163					263					363		7	22	32
Nalidixic acid	O	167					267	1			1	367	7		2	10
Nitrofurantoin	U	171	34	4	24	67	271	24	30	59	117	371	66	8	2	81
Norfloxacin	U	173					273					373	41	8	5	59
Ofloxacin	U	174					274					374	12		2	15
Piperacillin	B	179	1			1	279	1		1	2	379	11	13	27	56
Piperacillin/Tazobactam	B	181		2		2	281		1	1	2	381	10	20	44	81
Sulfisoxazole	U	186					286					386	10	1	1	12
Tetracycline	C	189	1			1	289	1			1	389	88	29	47	177
Ticarcillin/clavulanate	B	192					292			2	2	392	5	11	28	48
Tobramycin	A	194		1		1	294					394	24	23	70	126
Trimethoprim	U	195					295					395	10		6	18
Trimethoprim/sulfameth	B	197			1	1	297					397	142	43	98	300

**Correct responses for Antimicrobial Susceptibilities are defined as those reflecting agreement among 90% or more of all participants. Unacceptable responses are demonstrated by shading.**

\* CLSI suggested grouping of U. S. FDA-Approved Antimicrobial Agents that should be considered for routine testing and reporting on this organism.

Group A - Primary Test & Report

Group B - Primary Test, Report Selectively

Group O - Other, Not Routine, Clinical Indication for Organism Group

Group C - Supplemental, Report Selectively

Group U - Supplemental, For Urine Only

Per CMS requirements, participants will be flagged for inappropriate selection of Antimicrobial Agents as listed in CLSI (NCCLS) guidelines M2-A8 and M7-A6. Scoring will be affected by selection of an incorrect Antimicrobial and will be counted as incorrect whether or not the organism's antimicrobial susceptibility was determined correctly. Antimicrobial agents that are not listed in the CLSI guidelines as appropriate for the identified organism that were reported are:

Azithromycin  
Azlocillin

Cephalexin  
Moxifloxacin  
Nafcillin

Neomycin  
Teicoplanin